IGHE and anaphylaxis: BTK has been especially studied as a therapeutic target for MC-related diseases with promising data: irreversible BTK inhibitors have been shown to prevent IgE-mediated degranulation and cytokine production in MCs, block allergen-induced contraction of isolated human bronchi and, in a mouse model, prevent moderate IgE-mediated anaphylaxis and protect against death during severe anaphylaxis [27,28].